These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Forthcoming therapeutic perspectives for infections due to multidrug-resistant Gram-positive pathogens. Cornaglia G; Rossolini GM Clin Microbiol Infect; 2009 Mar; 15(3):218-23. PubMed ID: 19335369 [TBL] [Abstract][Full Text] [Related]
3. The changing epidemiology of resistance. Hawkey PM; Jones AM J Antimicrob Chemother; 2009 Sep; 64 Suppl 1():i3-10. PubMed ID: 19675017 [TBL] [Abstract][Full Text] [Related]
4. The epidemiology of antibiotic resistance. Gould IM Int J Antimicrob Agents; 2008 Nov; 32 Suppl 1():S2-9. PubMed ID: 18757182 [TBL] [Abstract][Full Text] [Related]
5. Minocycline--an old drug for a new century: emphasis on methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii. Bishburg E; Bishburg K Int J Antimicrob Agents; 2009 Nov; 34(5):395-401. PubMed ID: 19665876 [TBL] [Abstract][Full Text] [Related]
6. Fighting infections due to multidrug-resistant Gram-positive pathogens. Cornaglia G Clin Microbiol Infect; 2009 Mar; 15(3):209-11. PubMed ID: 19335367 [TBL] [Abstract][Full Text] [Related]
7. What's new on the antimicrobial horizon? Song JH Int J Antimicrob Agents; 2008 Dec; 32 Suppl 4():S207-13. PubMed ID: 19134521 [TBL] [Abstract][Full Text] [Related]
9. [Blood isolates epidemiology in a clinical haematology department]. Elmaataoui A; Elghazouani M; Eric NA; Doghmi K; Mikdame M; Elhamzaoui S; Elouennass M Ann Biol Clin (Paris); 2009; 67(3):293-7. PubMed ID: 19411231 [TBL] [Abstract][Full Text] [Related]
10. Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures, including recent pharmacodynamic considerations. Biedenbach DJ; Jones RN Diagn Microbiol Infect Dis; 2009 Jun; 64(2):202-12. PubMed ID: 19321284 [TBL] [Abstract][Full Text] [Related]
11. Iclaprim, a novel diaminopyrimidine for the treatment of resistant gram-positive infections. Sincak CA; Schmidt JM Ann Pharmacother; 2009 Jun; 43(6):1107-14. PubMed ID: 19435963 [TBL] [Abstract][Full Text] [Related]
12. Epidemiological and resistance issues in multidrug-resistant staphylococci and enterococci. Leclercq R Clin Microbiol Infect; 2009 Mar; 15(3):224-31. PubMed ID: 19335370 [TBL] [Abstract][Full Text] [Related]
13. Tackling antibiotic resistance: a dose of common antisense? Woodford N; Wareham DW; J Antimicrob Chemother; 2009 Feb; 63(2):225-9. PubMed ID: 19004840 [TBL] [Abstract][Full Text] [Related]
14. [The rate of inducible clindamycin resistance and susceptibilities to other antimicrobial agents in staphylococci]. Oğuz VA; Yapar N; Sezak N; Cavuş SA; Kurutepe S; Peksel H; Cakir N; Yüce A Mikrobiyol Bul; 2009 Jan; 43(1):37-44. PubMed ID: 19334378 [TBL] [Abstract][Full Text] [Related]
15. New strategies for combating multidrug-resistant bacteria. Wright GD; Sutherland AD Trends Mol Med; 2007 Jun; 13(6):260-7. PubMed ID: 17493872 [TBL] [Abstract][Full Text] [Related]